$350m Adaptimmune deal shows GSK still does cancer R&D

GlaxoSmithKline, recently assumed by some industry commentators to be exiting oncology, has signed a deal with immunotherapy company Adaptimmune which could be worth more than $350m. The collaboration underlines GSK's stated ambition to pour major investment into immuno-oncology.